EXHIBIT 10.81
RESEARCH COLLABORATION AND LICENSE AGREEMENT
This Agreement, dated December 10, 1997, is by and between SMITHKLINE
XXXXXXX PLC (hereinafter referred to as "SB"), a company whose registered
office is at Xxx Xxxxxxxx Xxxxx, Xxxxxxxxx, Xxxxxxxxx, XX00XX, Xxxxxx
Xxxxxxx, and MEDIMMUNE, INC., a Delaware Corporation, located at 00 Xxxx
Xxxxxxx Xxxx Xxxx, Xxxxxxxxxxxx, Xxxxxxxx 00000 ("MEDIMMUNE").
WHEREAS, MEDIMMUNE is the owner or licensee of certain technology,
including, but not limited to patents and proprietary know-how, relating to
vaccines for the human papilloma virus (AHPV@); and
WHEREAS, SB desires to obtain, and MEDIMMUNE desires to grant to SB, a
worldwide, exclusive right and license in and to such technology, on the
terms and conditions set forth in this Agreement; and
WHEREAS, SB will collaborate with MEDIMMUNE in a research and
development program relating to (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
HPV Vaccines to support ongoing development thereof and to obtain
intangible rights thereto, and
WHEREAS SB will contribute certain adjuvant technology and certain HPV
technology to the research program.
NOW, THEREFORE, in consideration of the mutual promises and other good
and valuable consideration, the parties agree as follows:
SECTION I.. - DEFINITIONS.
The terms used in this Agreement have the following meaning:
1.1 "Affiliate", with respect to any Party, shall mean any Person
whether de jure or de facto, controlling, controlled by, or under common
control with, such Party. For these purposes, "control" shall refer to (a)
the possession, directly or indirectly, of the power to direct the
management or policies of a Person, whether through the ownership of voting
securities, by contract or otherwise or (b) the ownership, directly or
indirectly, of at least 50% (or such lesser percentage which is the maximum
allowed to be owned by a foreign corporation in a particular jurisdiction
of the voting securities or other ownership interest of a Person.
1.2 "Annual Research Plan" shall mean the research plan prepared
annually during the term of the Research Program as provided in Section
4.2.
1.3 "Antigen" shall mean (i) HPV antigens and/or (ii) HPV proteins
and/or (iii) other physical forms based on such antigens, such as peptides
and/or nucleic acid(s) (DNA, RNA) delivered in any form including
recombinant vectors.
1.4 "Budget" shall have the meaning assigned to such term in Section
4.2.
1.5 "Confidential Information" shall have the meaning assigned to
such term in Section 11.2.
(PAGE 1)
1.6 "Effective Date" shall mean the date set forth in Section 2.1 of
this Agreement.
1.7 "EMEA" shall mean the European Agency for the Evaluation of
Medicinal Products.
1.8 "FDA" shall mean the United States Food and Drug Administration,
or the successor thereto.
1.9 "First Commercial Sale" shall mean, with respect to any Vaccine
Product in a country of the Territory, the first sale by SB, its
Affiliates, distributors or sublicensees to a Third Party of such Vaccine
Product, in such country anywhere in the Territory after all required
marketing and pricing approvals have been granted, or otherwise permitted,
by the governing health authority of such country. "First Commercial Sale"
shall not include the sale of any Vaccine Product for use in clinical
trials or for compassionate use prior to the grant of regulatory approval.
1.10 "HPV Vaccine" shall mean a vaccine for the prevention, control or
treatment of human papilloma virus infection in humans in any formulation,
configuration or delivery system or a product or process for the diagnosis
of HPV infection in humans.
1.11 "IND" shall mean an investigational new drug application filed
with the FDA for approval to commence human clinical trials, or the
equivalent application in other countries or regulatory jurisdictions.
1.12 "Invention" shall mean any new or useful process, manufacture,
compound or composition of matter, patentable or unpatentable, or any
improvement thereof, conceived or first reduced to practice, by either
Party during the conduct of the Research Program (i) which relate to or are
derived from the Research Program, or (ii) which are necessary or useful to
make, use, develop or sell HPV Vaccine.
1.13 "Major Markets" shall have the meaning assigned thereto in
Section 6.3.
1.14 "Joint Invention" shall mean any Invention for which it is
determined, in accordance with applicable United States patent law, that
both: (i) one or more employees or agents of MEDIMMUNE or any other
persons obliged to assign such Invention to MEDIMMUNE, and (ii) one or more
employees or agents of SB or any other persons obliged to assign such
Invention to SB, are joint inventors of such Invention.
1.15 "MEDIMMUNE Patents" shall mean any and all patents or patent
applications anywhere in the world, including but not limited to any
division, continuation, continuation-in-part or reissue, re-examination,
patent extension, or Supplementary Protection Certificate in each case
which is owned by or licensed to MEDIMMUNE and in and to which MEDIMMUNE
has a transferable interest on the Effective Date or at any time during the
term of this Agreement (including those arising from the Research Program)
insofar as it contains one or more claims to MEDIMMUNE Technology or to a
Joint Invention. Schedule A contains the list of MEDIMMUNE patents
licensed to and/or owned by MEDIMMUNE on the Effective Date.
(PAGE 2)
1.16 The term "MEDIMMUNE Technology" shall mean information, know-how
and materials, including, but not limited to, pharmaceutical, chemical and
biological products, technical and non-technical data and information (i)
owned by MEDIMMUNE and/or to which MEDIMMUNE has a transferable interest on
the Effective Date and/or at any time during the term of this Agreement and
(ii) which relate to the field of (CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED) HPV Vaccines and/or which arise from the Research Program, and
in each case which are necessary or useful for the development,
manufacture, use or sale of an HPV Vaccine.
1.17 "Net Sales" (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
1.18 "Party" shall mean MEDIMMUNE or SB and, when used in the plural,
shall mean MEDIMMUNE and SB.
1.19 "Patent" shall mean individually and collectively SB Patents and
MEDIMMUNE Patents.
1.20 "Person" shall mean any natural person, corporation, firm,
business trust, joint venture, association, organization, company,
partnership or other business entity, or any government or any agency or
political subdivision thereof.
1.21 "Process" shall mean any process or method for the production,
manufacture or use of any HPV Vaccine.
1.22 "Product Registrations" shall mean the approvals or registrations
of Vaccine Products in any country in the Territory that are received by SB
during the term of this Agreement.
1.23 "Research Program" shall mean the research program directed to
the research, development, and manufacture of a therapeutic and/or
prophylactic (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) Vaccine Product up
to and including Phase II clinical trials to be conducted by MEDIMMUNE in
collaboration with SB pursuant to Section 4.2 of this Agreement..
1.24 "Research Term" shall have the meaning assigned to such term in
Section 4.7.
1.25 "Royalty Term" shall mean, (CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED)
1.26 The term "SB Patents" shall mean any patent or patent application
anywhere in the world, including but not limited to any division,
continuation, or continuation-in-part reissue, re-examination, patent
extension, or Supplementary Protection Certificate which is owned by or
licensed to SB or its Affiliates and in and to which SB or its Affiliates
has a transferable interest on the Effective Date or at any time during the
term of this Agreement insofar as it contains one or more claims to SB
Special Technology or to a Joint Invention. SB or its Affiliates shall
have the right but not the obligation to file a Supplementary Protection
Certificate pertaining to SB Patents.
(PAGE 3)
1.27 The term "SB Technology" shall mean information and materials,
including, but not limited to, pharmaceutical, chemical and biological
products, technical and non-technical data and information owned by SB or
its Affiliates or to which SB or its Affiliates has a transferable interest
on the Effective Date and/or during the term of this Agreement which
relates to the field of (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) HPV
Vaccines and which are necessary or useful in the execution of the Research
Program, as defined by the Steering Committee.
1.28 "SB Special Technology" shall mean information and materials,
including, but not limited to, pharmaceutical, chemical and biological
products, technical and non-technical data and information owned by SB or
its Affiliates or to which SB or its Affiliates has a transferable interest
on the Effective Date and/or prior to termination of this Agreement which
is derived from use of MEDIMMUNE Technology provided to SB or its
Affiliates or which comes out of the Research Program.
1.29 "Steering Committee" shall mean the entity organized and acting
pursuant to Section 3.
1.30 "Sublicensee" shall mean a Third Party to which SB has granted
sublicense and/or sub-sublicense rights under the licenses and/or
sublicenses granted to SB hereunder.
1.31 "Supplementary Protection Certificate" shall mean the
supplementary protection certificate for Medicinal products and their
equivalents provided under Control Regulation (EEC) No. 1768/92 of June 18,
1992.
1.32 "Territory" shall mean the entire world.
1.33 "Third Party" shall mean any Person who or which is neither a
Party nor an Affiliate of a Party.
1.34 "Vaccine Product" shall mean an HPV Vaccine (x)covered in whole
or in part by a MEDIMMUNE Patent or an SB Patent which covers SB Special
Technology and/or (y) which incorporates or is derived from the use of
MEDIMMUNE Technology and/or SB Special Technology. (CONFIDENTIAL TREATMENT
HAS BEEN REQUESTED).
1.35 "Interpretative Rules" For the purpose of this Agreement, except
as otherwise expressly provided herein or unless the context otherwise
requires : (a) defined terms include the plural as well as the singular and
the use of any gender shall be deemed to include the other gender. (b)
references to "Articles", "Sections" and other subdivisions and to
"Schedules" and "Exhibits" without reference to a document, are to
designated Articles. Sections and other subdivisions of and to Schedules
and Exhibits to this Agreement; (c) the use of the term 'including' means
'including but not limited to'; and (d) the words 'herein', 'hereof',
'hereunder' and other words of similar import refer to this Agreement in
whole and not to any particular provision.
(PAGE 4)
2. GRANT OF LICENSES AND EFFECTIVE DATE.
2.1 (a) The obligations of each of SB and MEDIMMUNE to consummate
the transactions contemplated by this Agreement shall be subject to the
fulfillment of the condition that the waiting period (and any extension
thereof) under the Xxxx-Xxxxx-Xxxxxx Antitrust Improvements Act of 1976, as
amended, and the rules and regulations promulgated thereunder applicable to
the transaction contemplated hereby shall have expired or shall have been
terminated and that no action shall have been instituted, or shall be
threatened or pending, by the United States Justice Department or the
Federal Trade Commission challenging or seeking to enjoin the consummation
of the transactions contemplated by this Agreement, which action shall not
have been withdrawn or terminated. The date which is the later of January
2, 1998 or the date on which the aforesaid condition has been satisfied is
referred to herein as the "Effective Date".
(b) The Parties agree to promptly complete any filings with
respect to the contingencies of Section 2.1(a) and to exert reasonable
efforts to fulfill the conditions contemplated by Section 2.1(a).
(c) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
2.2 License.
(a) MEDIMMUNE hereby grants to SB and its Affiliates an
exclusive, royalty-bearing license throughout the Territory, with the right
to grant sublicenses in accordance with the terms of this Agreement, under
MEDIMMUNE's interest in the MEDIMMUNE Patents, MEDIMMUNE Technology and
Joint Inventions, to develop, register, use, make, have made, import,
export, offer to sell, sell and have sold HPV Vaccines and/or Antigens
and/or Process.
(b) SB agrees that it will use MEDIMMUNE Technology and
MEDIMMUNE Patents only as licensed under this Agreement.
(c) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
2.3 Sublicensing by SB.
(a) SB shall have the right to grant sublicenses to a Third
Party under the license granted pursuant to Section 2.2 provided that: (i)
SB shall guarantee and be responsible for the making of all payments due,
and the making of reports under this Agreement, by reason of milestones
achieved with respect to any Vaccine Product and sales of any Vaccine
Products by its Sublicensees and their compliance with all applicable
licensing terms of this Agreement to the extent that they are applicable to
a Sublicensee; and (ii) each Sublicensee agrees in writing to comply
withSections 8.3, 8.4, 10, 11.2 and 11.3 of this Agreement. It is
understood that SB shall not grant a sublicense to a single Third Party of
all of its rights in the Major Markets under Section 2.2 without the
written consent of MEDIMMUNE.
(b) SB hereby unconditionally guarantees the performance of
any of its Affiliates and its Sublicensees hereunder as if they were
signatories to this Agreement to the extent the performance or lack of
performance is a breach of this Agreement.
(PAGE 5)
(c) Any sublicense granted by SB to a Third Party shall
include a provision prohibiting further sublicenses and a provision
terminating the sublicense when the license to SB terminates.
2.4 Third Party Agreements
(a) To the extent MEDIMMUNE Technology and MEDIMMUNE Patents
licensed by SB under this Agreement are rights which MEDIMMUNE has licensed
from a Third Party, under an agreement with such Third Party listed in
Schedule B ("Third Party Agreement(s)"), SB understands and agrees as
follows:
(i) The rights licensed to SB by MEDIMMUNE are subject to
the terms, limitations, restrictions and obligations of the Third Party
Agreement(s).
(ii) SB will comply with all of the terms, obligations,
limitations and restrictions of the Third Party Agreement(s) which are
applicable to a sublicensee under such Third Party Agreements. In the case
of the sublicense granted by this Agreement to SB under the (CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED) Agreement (as defined below), the sublicense
granted by SB shall terminate or be converted to a license directly between
SB and (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) at the option of SB upon
termination of this Agreement provided that such conversion is subject to
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) approval and contingent upon
acceptance by SB of the provisions of the (CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED) License Agreement.
(iii) SB will cooperate with MEDIMMUNE in furnishing
all information and data which are reasonably required to enable MEDIMMUNE
to meet its reporting requirements under the Third Party Agreements.
(iv) To the extent the MEDIMMUNE Technology and MEDIMMUNE
Patents licensed by SB under this Agreement are rights that MEDIMMUNE has
licensed under the (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) License
Agreement, SB acknowledges and agrees that the obligations to (CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED) set forth in Paragraphs 4.01, 6.01, 8.01,
8.02, 10.05, 11.06-11.08 and 12.08 of the (CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED) License Agreement, the text of which Paragraphs are attached as
Exhibit A shall be binding upon SB as if it were a party thereto.
(v) The Parties acknowledge the rights of a sublicensee
under Section 10.5 of the (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
Agreement and Section 13.7 of the (CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED) Agreement as referred to in Schedule B.
(b) The Third Party Agreements which exist on the Effective
Date are listed in Exhibit B and SB acknowledges receipt of such Third
Party Agreements. MEDIMMUNE warrants that the Third Party Agreements
listed in Exhibit B are all the agreements entered into by MEDIMMUNE with
respect to HPV Vaccines and no further modifications to said agreements
have been made up to the Effective Date and said agreements are in full
force and effect. As of the date of this Agreement, to the knowledge of
MEDIMMUNE, MEDIMMUNE is not in breach of any such Third Party Agreements,
provided, however, that
(PAGE 6)
a breach of this warranty shall only occur if a Third Party Agreement is
terminated as a result of such breach.
(c) Upon mutual agreement of the Parties, MEDIMMUNE may
terminate any or all Third Party Agreements and the licenses granted to SB
thereunder. After First Commercial Sale of a Vaccine Product in any of the
following countries: United States, United Kingdom, France, Germany, Italy
or Spain, SB may terminate its sublicense under the following agreements
and its payment obligations and other obligations hereunder with respect to
such agreements: (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)and the
payment obligations thereunder. Upon termination of any such sublicense,
SB shall return to MEDIMMUNE all information and materials which were
provided to SB pursuant to such sublicense.
3 STEERING COMMITTEE.
3.1 Members. The Parties shall establish the Steering Committee
(the "Steering Committee"), which shall be comprised of six members, three
representatives designated by each Party. The members of the Steering
Committee may be represented at any meeting by a designee appointed by such
member for such meeting. The chairperson of the Steering Committee shall
be designated annually on an alternating basis between the Parties. The
initial chairperson shall be selected by SB. The Party not designating the
chairperson shall designate one of its representative members as secretary
to the Steering Committee for such year. Each Party shall be free to
change its representative members on notice to the other Party.
3.2 Responsibilities. The Steering Committee shall be responsible
for overseeing the Research Program in a manner which is consistent with
the terms and conditions of this Agreement, including, without limitation:
(a) to evaluate and determine scientific criteria to be
implemented under the Research Program;
(b) to review, approve and modify any Annual Research Plan,
and any Budget included therein;
(c) to review and evaluate progress under the Research
Program;
(d) to provide for the exchange of information and materials
relating to the Research Program; and
(e) to coordinate and monitor publication of research results
arising from the Research Program.
3.3 Meetings. The Steering Committee shall meet at least four
times every calendar year, and more frequently as the Parties deem
appropriate, on such dates and at such times as the Parties shall agree.
Meetings may also be called by either Party, on 10 days written notice to
the other, unless such notice is waived by the Parties. The meetings shall
alternate between the offices of the Parties unless the Parties otherwise
agree. The chairperson shall be responsible for sending notices of
meetings to all members. The Steering Committee may also convene or be
polled or consulted
(PAGE 7)
from time to time by means of telecommunications, video conferences or
correspondence, as deemed necessary or appropriate. Two weeks prior to
each of the four Steering Committee meetings, a summary of progress under
the Research Program shall be provided by MEDIMMUNE to the members of the
Steering Committee.
3.4 Decisions.
(a) All decisions of the Steering Committee shall be made by
unanimous agreement of the members present in person or by telephone at any
meeting, with the MEDIMMUNE members cumulatively having one vote and the SB
members cumulatively having one vote. A quorum for a meeting shall require
at least one representative from MEDIMMUNE and at least one representative
from SB.
(b) In the event that unanimity cannot be reached by the
Steering Committee with respect to a matter that is subject to its decision-
making authority, then the matter shall be referred for further review and
resolution to the Senior Vice President of SmithKline Xxxxxxx Biologicals
SA, xxx xx x'Xxxxxxxx 00, 0000 Xxxxxxxxx, or such other similar position
designated by SB from time to time, and the President at MEDIMMUNE, or such
other similar position designated by MEDIMMUNE from time to time. The
designated officers of each Party shall use reasonable efforts to resolve
the matter within 30 days after the matter is referred to them.
(c) In the event the designated officers fail to resolve the
matter in accordance with paragraph (b) above, the decision of SB's Senior
Vice President shall prevail in all cases, provided that in each case such
decision of the officer of SB is consistent with the terms and conditions
of this Agreement.
(d) Notwithstanding the foregoing, neither Party shall be
required to conduct any clinical trials where such Party has significant
safety or ethical objections thereto.
3.5 Minutes. Within 15 days after each Steering Committee meeting,
the secretary of the Steering Committee shall prepare and distribute
minutes of the meeting, which shall provide a description in reasonable
detail of the discussions had at the meeting and a list of any actions,
decisions or determinations approved by the Steering Committee. The
secretary shall be responsible for circulation of all draft and final
minutes. Draft minutes shall be first circulated to the chairperson,
edited by the chairperson and then circulated in final draft form to all
members of the Steering Committee sufficiently in advance of the next
meeting to allow adequate review and comment prior to the meeting. Minutes
shall be approved or disapproved, and revised as necessary, at the next
meeting. Final minutes shall be distributed to the members of the Steering
Committee.
3.6 Term. The Steering Committee shall exist until the termination
or expiration of the Research Program or for such longer period as
necessary to perform the responsibilities assigned to it under this
Agreement.
3.7 Expenses. Each Party shall be responsible for all travel and
related costs for its representatives to attend meetings of, and otherwise
participate on, the Steering Committee.
(PAGE 8)
4. COLLABORATIVE RESEARCH PROGRAM.
4.1 Exchange of Data and Know-How. Within forty-five (45) days
after the first meeting of the Steering Committee, MEDIMMUNE and SB shall
deliver to each other copies of all MEDIMMUNE Technology and SB Technology
respectively in their possession available as of such date which in each
case is necessary for the conduct of the Research Program. During the term
of this Agreement, each party shall provide promptly to the other any
subsequently acquired MEDIMMUNE Technology, SB Special Technology and SB
Technology as such is developed or acquired provided that the transfer of
SB Technology shall be subject to the determination of the Steering
Committee. SB will agree to use its adjuvant and formulation technology in
the Research Program but will not be obligated to disclose such adjuvant or
formulation technology to MEDIMMUNE, except as may be required by
applicable regulatory, laws, rules or regulations.
4.2 Scope of Research Program.
(a) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(b) Within sixty (60) days of the signing of this Agreement
with respect to the first year of the Research Term, and thereafter on each
anniversary of the date of this Agreement during the Research Term, the
Steering Committee shall prepare and provide to each Party, in the form and
substance mutually acceptable to each Party, a detailed description of the
specific Research Program to be undertaken during the upcoming year, which
shall include a reasonably detailed description of the goals and scope of
such research, a research plan and a budget (the "Budget"), which shall be
equal to the amount reinvested by MEDIMMUNE pursuant to the provisions
contained in Section 4.3, that details the equipment, materials, and
personnel to be provided by MEDIMMUNE at its fully allocated cost as well
as Third Party contractors to support the research described in such
proposal (an "Annual Research Plan"). Once agreed upon, each such Annual
Research Plan shall be signed and dated by both Parties. The Annual
Research Plan for the first year of the Research Term shall be signed by
the Parties simultaneously within sixty (60) days of execution of this
Agreement. The Steering Committee shall commence preparing each Annual
Research Plan (other than the first Annual Research Plan) not later three
months prior to each anniversary of this Agreement during such term.
Exhibit C is a preliminary outline of the Annual Research Plan for 1998.
(c) If the Steering Committee fails to agree in accordance
with the provisions of Section 3.4 on an Annual Research Plan: (i) SB shall
nevertheless continue to provide payment to MEDIMMUNE in accordance with
Section 6.1 (b), (ii) MEDIMMUNE shall nevertheless continue to conduct the
Research Program in accordance with the goals and scope of such research as
reasonably determined by SB, and in accordance with the Research Program as
described in Schedule C provided that such goals and scope shall be with
respect to Vaccine Products within the scope of the level of reinvestment
committed by MEDIMMUNE pursuant to Section 4.3 and within the scope of the
Research Program conducted to date, and (iii) MEDIMMUNE shall continue to
reinvest the amounts set forth in Section 4.3.
4.3 MEDIMMUNE shall reinvest the payments received from SB pursuant
to Section 6.1(b) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED), with a
(PAGE 9)
minimum reinvestment of (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED). If
mutually agreed upon by the Parties in the Steering Committee and assuming
SB can perform the work in a cost effective and timely manner, up to
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED). MEDIMMUNE shall use said
reinvestment for the execution of the Research Program.
4.4 Conduct of Research Program. During the Research Term,
MEDIMMUNE shall:
(a) undertake Research Program with SB as set forth in
Schedule C as further completed in any Annual Research Plan, and such other
activities which, from time to time, the Steering Committee decides as
being necessary for the success of the Research Program, provided that such
decision is consistent with the Research Program and the terms and
conditions of this Agreement, including, but not limited to:
(i) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(ii) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(iii)(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(iv) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED),
(v) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(vi) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(b) use all reasonable best efforts and proceed diligently to
perform the work set out for MEDIMMUNE to perform in the Annual Research
Plan. It is the intention of the parties to proceed in a cost-effective
manner and to achieve in a timely manner the objectives of the Research
Program.
(c) conduct the Research Program in accordance with the Annual
Research Plan in a good scientific manner, and in compliance in all
material respects with all requirements of applicable laws, rules and
regulations;
(d) promptly provide an invention disclosure report to SB with
respect to any Invention or Joint Invention;
(e) allow representatives of SB, upon reasonable notice and
during normal business hours, to visit the facilities of MEDIMMUNE where
the Research Program is being conducted, to facilitate transfer of
MEDIMMUNE Technology and to consult informally, during such visits and by
telephone, with MEDIMMUNE's personnel performing work on the Research
Program.
(f) apply the reinvestments detailed under Section 4.3 to
conduct the Research Program, carry out its obligations in connection with
the Research Program and accomplish the goals and objectives for the
Research Program ;
(g) It is expressly understood and agreed that MEDIMMUNE shall
not be required to perform research under the Research Program in any year
(PAGE 10)
beyond the total amount of reinvestments committed by MEDIMMUNE pursuant to
Section 4.3 for that year; and
(h) SB understands and acknowledges and agrees that the
Research Program is experimental and research under the Research Program
may not achieve the overall goals in any year or the overall goals of the
Research Program and that MEDIMMUNE has no liability with respect to any
failure of the Research Program to develop a Vaccine Product.
4.5 Records.
(a) MEDIMMUNE shall maintain records, in sufficient detail and
in good scientific manner, which shall be complete and accurate in all
material respects and shall fully and properly reflect all work done and
results achieved in the performance of the Research Program (including all
data in the form required under all applicable laws and regulations).
MEDIMMUNE shall provide a quarterly report.
(b) SB shall have the right, during normal business hours and
upon reasonable notice, to inspect and copy all such records of MEDIMMUNE
relating to the Research Program to the extent reasonably required for the
performance of its obligations under this Agreement. SB shall maintain
such records and the information contained therein in confidence in
accordance with Section 11.2 and shall not use such records or information
except to the extent otherwise permitted by this Agreement.
4.6 Inventions.
Joint Inventions shall be jointly owned by both parties. Inventions
which arise from the Research Program and which are made by an employee or
agent of MEDIMMUNE, solely or jointly, other than with an employee or agent
of SB shall be owned by MEDIMMUNE; Inventions which arise from the
Research Program and which are made by an employee or agent of SB, solely
or jointly other than with an employee or agent of MEDIMMUNE shall be owned
by SB. Except as provided otherwise herein, SB and MEDIMMUNE shall retain
their respective unrestricted rights to make, have made, use and sell such
Inventions which are owned by them solely.
4.7 Term of Research Program. The term of the Research Program
shall commence on January 1, 1998, and, subject to Section 4.8 shall
continue, except as otherwise provided in this Agreement, for a period of
five years thereafter (the "Research Term").
4.8 Termination of Research Program.
(a) In the event that MEDIMMUNE fails to use reasonable best
efforts to perform its research under the Research Program and such failure
materially affects the Research Program, such failure shall entitle SB to
give notice to MEDIMMUNE specifying the nature of the default and requiring
it to cure such default. If such default is not cured within 60 days after
the receipt of such notice (or, if such default cannot be cured within such
60-day period, if MEDIMMUNE does not commence and diligently continue
actions to cure such default), SB shall be entitled to terminate this
Agreement under Section 12.2 or the Research Program by giving written
notice to take effect immediately upon delivery of such notice. SB's right
(PAGE 11)
to terminate the Research Program or this Agreement, as hereinabove
provided, shall not be affected in any way by its waiver or failure to take
action with respect to any previous default. The termination of the
Research Program or this Agreement is the sole and exclusive remedy for any
such default. The termination of the Research Program or this Agreement
shall terminate SB's payment obligation under Section 6.1(b) except for the
portion thereof which has been committed to the funding of Third Parties
under the Research Program. To the extent MEDIMMUNE has received payments
under Section 6.1(b) which have been allocated to the Research Program
pursuant to Section 4.3 but which are not committed to Third Parties and
which have not been spent on the date of termination, such funds shall be
refunded to SB.
(b) Upon termination of the Research Program pursuant to
Section 4.8 (a) without termination of the Agreement, MEDIMMUNE shall and
shall cause its agents and Affiliates to promptly transfer to SB copies of
all data, reports, records and materials in MEDIMMUNE's possession or
control which relate to the scientific aspects of the Research Program.
Thereafter, SB shall have no further obligation to make payments under
Section 6.1(b). (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(c) Termination of the Research Program pursuant to this
Section 4.8 shall not affect SB's obligations to pay royalties, milestones
and other fees and payments as provided hereafter.
(d) For the avoidance of doubt, termination of the Research
Program shall not terminate any rights or obligations of the Parties under
this Agreement other than those set forth in this Section 4.8.
5. DEVELOPMENT AND COMMERCIALIZATION.
5.1 Development Efforts by SB. Upon the completion of the earlier
of the end of the Research Term or Phase II clinical trials with respect to
each Vaccine Product by MEDIMMUNE pursuant to the Research Program, SB
shall use reasonable best efforts (including, but not limited to, the
conduct of clinical trials, filing for Product Registrations and for other
regulatory approvals, diligently pursuing such approvals and, upon the
grant of regulatory approval, marketing the Vaccine Products) to develop
and commercialize such Vaccine Products throughout the Territory and
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED). SB shall make all
determinations regarding any development and commercialization activities
under this Section 5.1 in the sole and absolute discretion and control of
SB, provided that such activities are consistent with the efforts required
under this Section.
(i) During the term of the Agreement, MEDIMMUNE shall supply
MEDIMMUNE Technology and shall provide to SB technical assistance within
its area of expertise concerning the development, production and
commercialization of HPV Vaccine. Provision of such technical assistance
shall include but not be limited to visits by MEDIMMUNE personnel or agents
to SB at SB's expense and visits by SB personnel to MEDIMMUNE at SB's
expense.
(PAGE 12)
5.2 Responsibilities of SB
SB will be responsible for the following activities without limitation
at SB's cost and expense:
(i) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(ii) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(iii)(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(iv) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(v) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(vi) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(vii)(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
5.3 Liability by SB.
Except by reason of force majeure as provided in Section 13.1,
in the event that SB fails materially to satisfy its development and/or
marketing obligations under Sections 5.1 and 5.2 with respect to Vaccine
Product in any country of the Major Markets, MEDIMMUNE shall have at its
sole remedy the right and option to terminate this Agreement for the
concerned country of the Major Markets in its sole discretion in accordance
with Section 12.2(a).
5.4 Reporting.
SB shall provide to MEDIMMUNE an annual project status report
(including the status of regulatory approvals) of the development, and
registration of each Vaccine Product. All such reports by SB shall be
treated as Confidential Information of SB and shall be subject to the
restrictions imposed under Section 11.2.
5.5 MEDIMMUNE shall have the right to terminate this Agreement in
its entirety if
(i) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
6. FEE; MILESTONE PAYMENTS AND ROYALTIES.
6.1 (a) Fee by SB. In partial consideration of MEDIMMUNE Patents
and MEDIMMUNE Technology resulting from the use of the research performed
by MEDIMMUNE prior to this Agreement and the right to use pre-clinical and
clinical information developed by MEDIMMUNE, SB shall pay MEDIMMUNE a fee
of (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) on the Effective Date. In
addition, SB shall purchase MEDIMMUNE Common Stock from MEDIMMUNE for a
purchase price of (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) according to
the terms of the Stock Purchase Agreement attached hereto as Schedule D.
(PAGE 13)
(b) In further consideration of MEDIMMUNE Patents and
MEDIMMUNE Technology resulting from the use of the research performed by
MEDIMMUNE prior to this Agreement and the right to use preclinical and
clinical information developed by MEDIMMUNE prior to the Agreement and
rights to future developments of the Vaccine Product undertaken by
MEDIMMUNE during the term of the Agreement, SB agrees to provide a
Technology Access Fee to MEDIMMUNE. Such Technology Access Fee shall be
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED).
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED). Upon mutual agreement of
both parties, the above-mentioned payment schedule of the Technology Access
Fee may be accelerated. In each calendar year, the fee for the year shall
be paid in equal quarterly installments in advance on the first day of
January, April, July and October of each calendar year except the first
payment shall be made on the Effective Date. All payments shall be sent
via wire transfer to a bank account designated by MEDIMMUNE from time to
time. In the event that SB has paid (CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED) under this Section 6.1(b), SB will have met its payment
obligation under this Section 6.1(b). In the event any portion of this
Technology Access Fee is not timely made, all of the remaining fee shall
become due and payable immediately.
6.2 Development Milestone Payments by SB. In partial consideration
of the research performed by MEDIMMUNE prior to this Agreement and the
right to use pre-clinical and clinical information developed by MEDIMMUNE,
SB shall pay MEDIMMUNE the following milestone payments upon the first
occurrence of each event set forth below with respect to the first Vaccine
Product, whether achieved by SB or its Affiliates or its Sublicensees:
(a) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(b) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(c) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(d) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(e) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(f) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(g) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(i) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(ii) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(iii) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(iv) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(v) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(PAGE 14)
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
6.3 Royalties. In partial consideration of the rights and licenses
granted by MEDIMMUNE to SB under this Agreement, during the Royalty Term,
on a country-by-country and Vaccine Product-by Vaccine Product basis, SB
shall pay to MEDIMMUNE a royalty on Net Sales of Vaccine Products in an
amount equal to the following percentages of the specified portions of the
aggregate annual Net Sales of all Vaccine Products sold by SB, its
Affiliates, distributors and its Sublicensees throughout the Territory:
(i) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(ii) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(iii)(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(iv) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
In calculating the royalty due under this Section with respect to Net
Sales of Vaccine Products during any period of less than a calendar year,
the foregoing thresholds for a calendar year Net Sales shall be pro rated
in accordance with the duration of such period.
6.4 Third Party Compensation.
(a) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(b) With respect to any possible future license Agreements
between SB and a Third Party with respect to (CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED) HPV Vaccines, MEDIMMUNE shall notify SB, and SB shall
negotiate such Agreements and decide solely whether such technology is
required. SB shall pay all royalties and other compensation under any such
Agreement and MEDIMMUNE will not enter into such an Agreement without the
consent of SB.
(c) For the avoidance of doubt, SB shall not pay any
compensation or royalty for any Third Party Agreement pertaining to an HPV
Vaccine which (1) MEDIMMUNE enters during the Research Term without the
consent of the Steering Committee or (2) which MEDIMMUNE would enter into
after the Research Term.
(d) In the event that a dispute arises with a Third Party with
respect to the compensation owed to a Third Party under a Third Party
Agreement which is to be paid by SB pursuant to this Section 6.4, the
parties agree to cooperate with each other to reach a fair and equitable
resolution to such dispute.
6.5 Royalty Reduction. The royalties payable to MEDIMMUNE by SB
can be reduced only as follows:
If a Vaccine Product incorporates "Another Vaccine", which
is not covered by a MEDIMMUNE Patent to form a combination
product, then an adjusted royalty will be calculated based on
multiplying the Net Sales of the combination Vaccine Product by
the quotient 1/1+A, where A equals the total number of "Another
Vaccine"
(PAGE 15)
included in the combined product. In no event shall this
adjustment cause the royalty to be applied to less than 50% of
the Net Sales of the combined Vaccine Product. "Another
Vaccine" means a distinct proprietary product and does not
include HPV antigens or adjuvants.
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
6.6 Obligation to Pay Royalties. The obligation to pay royalties to
MEDIMMUNE under this Section 6 is imposed only once with respect to the
same unit of Vaccine Product regardless of the number of Patents pertaining
thereto. SB shall only be entitled to a credit against royalties or a
reduction of the royalty rate once with respect to any Vaccine Product in
any country pursuant to any provision in this Agreement. There shall be no
obligation to pay royalties to MEDIMMUNE under this Section 6 on sales of
Vaccine Products among SB and its Affiliates and its Sublicensees, but in
such instances the obligation to pay royalties shall arise upon the sale by
SB, its Affiliates or its Sublicensees to unrelated Third Parties.
6.7 In addition to all other compensation payable to MEDIMMUNE
under this Section 6, SB shall make a non-creditable minimum annual payment
to MEDIMMUNE of (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) due and payable
on January 1st of each year after termination of the Research Program and
until filing for regulatory approval for a Vaccine Product at the FDA or
its equivalent in the EU.
7. REPRESENTATIONS, WARRANTIES AND COVENANTS.
7.1 Representations and Warranties of Both Parties. Each Party
represents and warrants to the other Party that, as of the date of this
Agreement:
(a) Such Party is duly organized and validly existing under
the laws of the state of its incorporation and has full corporate power and
authority to enter into this Agreement and to carry out the provisions
hereof.
(b) The Third Party Agreements represent all rights and
licenses granted to MEDIMMUNE relating to HPV Vaccine which exist on the
Effective Date and MEDIMMUNE has provided SB with a true and complete copy
of such Third Party Agreements;
(c) MEDIMMUNE has not granted rights under MEDIMMUNE
Technology and/or MEDIMMUNE Patents to any Third Party which is in conflict
with the rights granted to SB pursuant to this Agreement.
(d) MEDIMMUNE acknowledges that in entering into this
Agreement, SB may have relied upon the technical or clinical information
provided to SB by MEDIMMUNE with respect to an (CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED) Vaccine Product. MEDIMMUNE has no present knowledge that
any of the technical or clinical information provided to SB by MEDIMMUNE
with respect to an (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) Vaccine
Product is inaccurate in any material respect.
(PAGE 16)
7.2 EXCEPT WITH RESPECT TO SECTION 2.4(b), MEDIMMUNE MAKES NO OTHER
REPRESENTATION OR WARRANTY HEREUNDER, INCLUDING, BUT NOT LIMITED TO,
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR USE OR WITH RESPECT TO THE
VALIDITY, ENFORCEABILITY, NON-INFRINGEMENT OF MEDIMMUNE PATENTS.
8. PAYMENTS AND REPORTS.
8.1 Royalty Payments. All royalty payments due hereunder shall be
paid quarterly within thirty (30) days of the end of each calendar quarter.
Each such payment shall be accompanied by a statement, Product-by-Product
and country-by-country, of the amount of Gross Sales, the calculation of
Net Sales and the units of Vaccine Product during such quarter, the amount
of royalties due on such Net Sales, the conversion rates used in converting
to United States Dollars and any other information reasonably requested by
MEDIMMUNE to enable MEDIMMUNE to determine amounts it is owed hereunder.
SB shall also provide MEDIMMUNE with a calculation and a report with
respect to royalties paid on behalf of MEDIMMUNE pursuant to Section 6.4.
8.2 Mode of Payment. All invoices and statements submitted by
MEDIMMUNE shall be stated in U.S. Dollars. SB shall make all payments
required under this Agreement as directed by MEDIMMUNE from time to time in
United States Dollars. Whenever for the purpose of calculating royalties
conversion from any foreign currency shall be required, such conversion
shall be at the average rate of exchange for the applicable calendar
quarter based on the daily rate of exchange published in the Wall Street
Journal, New York edition, for the applicable calendar quarter.
8.3 Records Retention. SB and its Affiliates and its Sublicensees
shall keep complete and accurate records pertaining to the sale of Vaccine
Products in the Territory and covering all transactions from which Net
Sales are derived for a period of three calendar years after the year in
which such sales occurred, and in sufficient detail to permit MEDIMMUNE to
confirm the accuracy of royalty payments due hereunder.
8.4 Audit Request. At the request and expense (except as provided
below) of MEDIMMUNE, SB and its Affiliates and its Sublicensees shall
permit an independent, certified public accountant appointed by MEDIMMUNE
and reasonably acceptable to SB, at reasonable times and upon reasonable
notice, to examine those records and all other material documents relating
to or relevant to Net Sales in the possession or control of SB or its
Affiliates or its Sublicensees, for a period of three years after such
royalties have accrued. Said accountant shall not disclose to MEDIMMUNE
any information other than information relating to said reports, royalties,
and payments. Results of any such examination shall be made available to
both Parties. If, as a result of any inspection of the books and records
of SB or its Affiliates or its Sublicensees, it is shown that SB's royalty
payments under this Agreement were less than the amount which should have
been paid, then SB shall make all payments required to be made to eliminate
any discrepancy revealed by said inspection within 45 days after
MEDIMMUNE's demand therefor. Furthermore, if the royalty payments were
less than the amount which should have been paid by an amount in excess of
5% of the royalty payments actually made during the period in question, SB
shall also reimburse MEDIMMUNE for the cost of such inspection.
(PAGE 17)
8.5 Taxes. It is understood that all payments required to be made
to MEDIMMUNE under this Agreement shall be paid by SB from the United
Kingdom and pursuant to the tax treaty, no taxes shall be withheld from any
such payment. In the event of a change in the treaty or law and in the
event that SB is thereafter required to withhold any tax to the tax or
revenue authorities in any country in the Territory regarding any payment
to MEDIMMUNE due to the laws of such country, such amount shall be deducted
from the royalty or other payment to be made by SB, and SB shall notify
MEDIMMUNE and promptly furnish MEDIMMUNE with copies of any tax certificate
or other documentation evidencing such withholding. Each Party agrees to
cooperate with the other Party in claiming exemptions from such deductions
or withholdings under any agreement or treaty from time to time in effect.
9. PATENT PROSECUTION; ENFORCEMENT; INFRINGEMENT.
9.1 Patent Filing, Maintenance and Prosecution.
(a) Representatives of MEDIMMUNE and SB shall discuss in which
countries Patents should be filed, prosecuted and/or maintained. The
Parties acknowledge and agree that they intend to file, prosecute and
maintain Patents in all major commercial markets where viable patent
protection is available (such countries shall be referred to as "Patent
Countries"). If the laws affecting patent protection or maintenance costs
change in any Patent Country, the Parties shall reassess the need to
continue to file, prosecute and maintain Patents in such country. If the
Parties determine to discontinue such filing, prosecution and maintenance
in any such country, such country shall no longer be deemed a Patent
Country.
(b) MEDIMMUNE or MEDIMMUNE licensors, in the case of MEDIMMUNE
Patents licensed to MEDIMMUNE, shall file, prosecute and maintain MEDIMMUNE
Patents in the Territory through patent counsel selected by MEDIMMUNE and
MEDIMMUNE, shall consult with and keep SB advised with respect thereto.
MEDIMMUNE shall disclose to SB the complete texts of all such patents and
patent applications filed by MEDIMMUNE or its licensor, as well as all
information received concerning the institution or possible institution of
any interference, opposition, re-examination, reissue, revocation,
nullification or any official proceeding involving any patent licensed
herein anywhere in the Territory. SB shall have the right to review such
pending applications and other proceedings and make recommendations to
MEDIMMUNE concerning them and their conduct. MEDIMMUNE agrees to keep SB
promptly and fully informed of the course of patent prosecution or other
proceedings including by providing SB with copies of substantive
communications, search reports and Third Party observations submitted to or
received from patent offices throughout the Territory. MEDIMMUNE shall
provide such patent consultation to SB at no cost to SB.
In the event MEDIMMUNE intends to finally abandon any MEDIMMUNE
Patents licensed to SB under this Agreement, it shall notify SB and SB
shall have the right at its own expense to assume responsibility for any
such patent or part of patent.
At SB's request, MEDIMMUNE and/or its licensors, as the case
may be, shall file an application for a Supplementary Protection
Certificate for MEDIMMUNE Patents. SB shall provide relevant marketing
authorizations as appropriate.
(PAGE 18)
(c) Notwithstanding anything in this Section 9.1, SB may, at
its discretion, elect to discontinue financial support of any MEDIMMUNE
Patent in any Patent Country, provided, however, that prior to taking such
action, SB will notify MEDIMMUNE of its intention at least 60 days prior to
the date on which any payment or action is due. In any Patent Country in
which SB has elected to discontinue its support of any MEDIMMUNE Patent,
MEDIMMUNE, upon receiving notice, may elect at its own expense to assume
all financial responsibility for the prosecution or maintenance of such
MEDIMMUNE Patent in such Patent Country. In such event, all SB's rights to
the MEDIMMUNE Patent will be deemed to have expired with respect to such
Patent Country upon MEDIMMUNE's receiving notice of SB's decision.
(d) Absent an election not to support the filing, prosecution
and/or maintenance of a Patent in any Patent Country, all costs and
expenses incurred under this Section 11.1 with respect to the filing,
prosecution and/or maintenance of Patents will be paid by SB. Included in
such costs and expenses are all reasonable costs for the prosecution,
issuance, and maintenance of such patent applications and patents issuing
thereon, and any divisional, continuation-in-part, reissue applications or
patents, patents-in-addition, patents-of-revalidation or the registrations
of any patent or the like.
9.2 Review of Patent Office Communications. With respect to any
Patents, each patent application, office action, response to office action,
request for terminal disclaimer, and request for reissue or reexamination
of any patent issuing from any patent application made by either Party
shall be provided to the other Party sufficiently prior to the filing of
such application, response or request to allow for review and comment by
such other Party. Each Party shall have the right to take any action that
in its judgment is necessary to preserve such Patents.
9.3 Patent Enforcement.
(a) Each Party shall notify the other promptly after such
Party becomes aware of any alleged infringement of any Patent in any
country in the Territory. If any of the Patents under which SB holds a
license hereunder is infringed by a Third Party, SB shall have the right
and option, but not the obligation, to bring an action for infringement, at
its sole expense, against such Third Party in the name of MEDIMMUNE and/or
in the name of SB, and to join MEDIMMUNE as a party plaintiff if required.
SB shall promptly notify MEDIMMUNE of any such infringement and shall keep
MEDIMMUNE informed as to the prosecution of any action for such
infringement. SB shall have the full control over the conduct of the
litigation including settlement thereof provided, however, that SB shall
make no decision, including, but not limited to, settlement which adversely
affects the validity or enforceability of the MEDIMMUNE Patents without the
written consent of MEDIMMUNE. It is understood that in the case of
MEDIMMUNE Patents sublicensed to SB, the rights of this Section 9.3(a) are
subject to the terms and restrictions of the Agreement(s) between MEDIMMUNE
and its licensors.
(b) In the event that SB does not institute an infringement
proceeding against an offending Third Party within 90 days after becoming
aware or receiving notice of any alleged infringement, then MEDIMMUNE shall
have the right and option, but not the obligation, to institute such an
(PAGE 19)
action and to retain any recovered damages.
(c) In any infringement suit either Party may institute to
enforce any Patents pursuant to this Agreement, the other Party hereto
shall, at the request of the Party initiating such suit, cooperate in all
respects and, to the extent possible, have its employees testify when
requested and make available relevant records, papers, information,
samples, specimens, and the like. All reasonable out-of-pocket costs
incurred in connection with rendering cooperation requested hereunder shall
be paid by the Party requesting cooperation.
(d) The costs and expenses of any action instituted pursuant
to this Section 9.3 (including reasonable fees of attorneys and other
professionals) shall be borne by the Party instituting the action, or, if
the Parties elect to cooperate in instituting and maintaining such action,
such costs and expenses shall be borne by the Parties in such proportions
as they may agree in writing. Each Party shall execute all necessary and
proper documents and take such actions as shall be appropriate to allow the
other Party to institute and prosecute such infringement actions (if such
other Party has the right to institute and prosecute such infringement
actions pursuant to this Section 9.3).
(e) In the event that either Party shall undertake the
enforcement and/or defense of any Patent, any award or compensation
(including the fair market value of non-monetary compensation) paid by
Third Parties as a result of such an infringement action (whether by way of
settlement or otherwise) shall be applied as follows: (i) first, to
reimbursement of each Party for all expenses incurred by each in connection
with such action, on a pro rata basis, and (ii) second, any remaining
balance shall be allocated to the Party undertaking the action, except that
such amount shall be deemed to be Net Sales hereunder, for which MEDIMMUNE
shall be entitled to receive a royalty as provided in this Agreement.
(f) SB shall not have the right to settle or compromise any
such action in a manner which adversely affects MEDIMMUNE Patents without
the written consent of MEDIMMUNE.
(g) SB at its sole discretion may decide to enter into a
license agreement with any Third Party pertaining to HPV Vaccines in order
to avoid an (alleged) infringement of Third Party patents. In case both
parties deem it necessary to acquire additional technology, the Steering
Committee will decide on entering into license agreements with Third
Parties.
9.4 Infringement Actions by Third Parties. In the event of the
institution of any suit by a Third Party against SB, its Affiliates or its
Sublicensees for patent infringement involving the use, sale, distribution
or marketing of any Vaccine Product in the Territory and such infringement
claim is a result of the use of the MEDIMMUNE Patents or MEDIMMUNE
Technology SB shall promptly notify MEDIMMUNE in writing of such suit. In
the event of all such actions SB shall defend such action at its own
expense, and MEDIMMUNE hereby agrees to assist and cooperate with SB, at
its own expense, to the extent necessary in the defense of such suit. SB
shall have the right to settle the suit or consent to an adverse judgment
thereto, in its sole discretion. During the pendency of such action, all
royalties
(PAGE 20)
due hereunder shall continue to be paid by SB. SB shall assume full
responsibility for the payment of any award for damages, or any amount due
pursuant to any settlement entered into by SB with such Third Party,
subject to the provisions of this Agreement with respect to the reduction
of royalties. Any and all damages and awards received by SB as a result
thereof (i.e., as a result of a counterclaim) shall be allocated between
the Parties in the same manner as provided in Section 9.3.
10. INDEMNIFICATION.
10.1 By MEDIMMUNE. MEDIMMUNE shall indemnify and hold SB, its
Affiliates and its Sublicensees, and each of their respective directors,
officers, employees, shareholders and agents, harmless from and against any
and all Third Party claims, suits or demands for liabilities, damages,
losses, costs and expenses (including the reasonable fees of attorneys and
other professionals) arising out of or resulting from:
any breach of a representation or warranty made by
MEDIMMUNE or negligence, recklessness or wrongful intentional
acts or omissions of MEDIMMUNE, or its Affiliates and their
respective directors, officers, employees and agents, in
connection with the work performed by MEDIMMUNE under the
Research Program.
10.2 By SB. SB shall indemnify and hold MEDIMMUNE and licensors of
MEDIMMUNE to the extent that SB is sublicensed hereunder and its directors,
officers, employees, shareholders and agents, harmless from and against
any and all Third Party claims, suits or demands for liabilities, damages,
losses, costs and expenses (including the reasonable fees of attorneys and
other professionals) arising out of or resulting from:
the development manufacture, use, distribution or sale of any
Vaccine Product by SB, its Affiliates, distributors or Sublicensees except
those losses which arise out of the negligence or intentional misconduct of
MEDIMMUNE.
10.3 Costs of Enforcement. As the parties intend complete
indemnification, all costs and expenses of enforcing any provision of this
Section 10 shall also be reimbursed by the indemnifying Party.
10.4 Conditions to Indemnification. A person or entity that intends
to claim indemnification under this Section (the "Indemnitee") shall
promptly notify the other Party (the "Indemnitor") of any loss, claim,
damage, liability or action in respect of which the Indemnitee intends to
claim such indemnification, and the Indemnitor shall assume the defense
thereof with counsel mutually satisfactory to the Indemnitee whether or not
such claim is rightfully brought; provided, however, that an Indemnitee
shall have the right to retain its own counsel, with the fees and expenses
to be paid by the Indemnitor if Indemnitor does not assume the defense, or
if representation of such Indemnitee by the counsel retained by the
Indemnitor would be inappropriate due to actual or potential differing
interests between such Indemnitee and any other person represented by such
counsel in such proceedings. The indemnity agreement in this Section
shall not apply to amounts paid in settlement of any loss, claim, damage,
liability or action if such settlement is effected without the consent of
the Indemnitor, which consent shall not be withheld or delayed
unreasonably.
(PAGE 21)
The failure to deliver notice to the Indemnitor within a reasonable time
after the commencement of any such action, only if prejudicial to its
ability to defend such action, shall relieve such Indemnitor of any
liability to the Indemnitee under this Section, but the omission so to
deliver notice to the Indemnitor will not relieve it of any liability that
it may have to any Indemnitee otherwise than under this Section. The
Indemnitee under this Section, its employees and agents, shall cooperate
fully with the Indemnitor and its legal representatives in the
investigations of any action, claim or liability covered by this
indemnification.
10.5 Any and all Sublicensees of SB shall agree to the same
indemnity as in Section 10.2 of this Agreement and MEDIMMUNE shall be made
a Third Party beneficiary therein.
11. PUBLICATION; CONFIDENTIALITY.
11.1 Publication.
(a) Both Parties recognize that each may wish to publish the
results of their work relating to the Research Program. However, both
Parties also recognize the importance of acquiring patent protection on
inventions prior to publication. Consequently, neither Party shall publish
or present the results of the Research Program with respect to any Vaccine
Product or of development studies without the permission of the Steering
Committee. If the Steering Committee is not in existence, the Parties
shall appoint appropriate representatives for this function. This Section
11.1(a) shall cease to apply with respect to any Vaccine Product upon the
commercial launch of such Vaccine Product.
(b) Each Party also agrees to delete from any such proposed
publication any technical or scientific Confidential Information of the
other Party upon such other Party's reasonable request.
(c) In any publication permitted under this Section 11.1, each
Party shall acknowledge its collaboration with the other Party under this
Agreement.
(d) Nothing in Section 11.1 shall prevent MEDIMMUNE: (i) in
connection with efforts to secure financing at any time during the term of
this Agreement, from issuing statements as to achievements made, and the
status of the work being done by the Parties, under this Agreement, so long
as such statements do not jeopardize the ability to obtain patent
protection on Inventions or disclose non-public technical or scientific
Confidential Information of SB; or (ii) from issuing statements that
MEDIMMUNE determines to be necessary, in the opinion of its external
counsel, to comply with applicable law (including the disclosure
requirements of the U.S. Securities and Exchange Commission, Nasdaq or any
other stock exchange on which securities issued by MEDIMMUNE are traded);
provided that MEDIMMUNE shall provide SB with a copy of the proposed text
of such statements sufficiently in advance of the scheduled release thereof
to afford SB a reasonable opportunity to review and comment upon the
proposed text.
11.2 Confidentiality; Exceptions.
(PAGE 22)
Except to the extent expressly authorized by this Agreement or
otherwise agreed in writing, the Parties agree that, the receiving Party,
its Affiliates and its Sublicensees, if any, shall use reasonable efforts
to keep, and to ensure that their officers and directors keep, completely
confidential and shall not publish or otherwise disclose and shall not use
for any purpose any information furnished to it by the other Party, its
Affiliates or its Sublicensees, if any, or developed under or in connection
with the Research Program pursuant to this Agreement, except to the extent
that it can be established by the receiving Party by competent proof that
such information: (i) is or hereafter becomes generally available to the
public other than by reason of any default by the receiving Party with
respect to its confidentiality obligations hereunder; (ii) was already
known to the recipient as evidenced by prior written documents in its
possession; (iii) is disclosed to the recipient by a Third Party who is not
in default of any confidentiality obligation to the disclosing Party; or
(iv) is independently developed by or for the receiving Party without
reference to or reliance upon the information furnished by the other Party
("Confidential Information"). Information disclosed by one Party to the
other shall remain the property of the disclosing Party.
11.3 Exclusions to Confidentiality. The restrictions contained in
Section 11.2 shall not apply to Confidential Information that (i) is
submitted by the recipient to governmental authorities to facilitate the
issuance of marketing approvals for a Vaccine Product, provided that
reasonable measures shall be taken to assure confidential treatment of such
information, if practicable; (ii) is provided by the recipient to Third
Parties under appropriate terms and conditions, including confidentiality
provisions equivalent to those in this Agreement, for consulting,
manufacturing, development, manufacturing, external testing, marketing
trials and sublicensing or potential sublicensing of Vaccine Product in
accordance with this Agreement; or (iii) is otherwise required to be
disclosed in compliance with applicable laws or regulations (including,
without limitation, to comply with SEC, Nasdaq or stock exchange disclosure
requirements) or order by a court or other regulatory body having competent
jurisdiction; provided that if a Party is required to make any such
disclosure of the other Party's Confidential Information it will, except
where impracticable for necessary disclosures, for example to physicians
conducting studies or to health authorities, give reasonable advance notice
to the other Party of such disclosure requirement and, except to the extent
inappropriate in the case of patent applications or otherwise, will use its
reasonable best efforts to secure confidential treatment of such
Confidential Information required to be disclosed.
11.4 Injunctive Relief. The Parties acknowledge that money damages
alone would not adequately compensate the disclosing Party in the event of
a breach by the receiving Party of this Section 11, and that, in addition
to all other remedies available to the disclosing Party at law or in
equity, it shall be entitled to seek injunctive relief for the enforcement
of its rights under this Section 11.
11.5 The obligations of this Article 11 shall terminate
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED) years after the termination of
this Agreement.
12. TERM; TERMINATION.
(PAGE 23)
12.1 Term. This Agreement shall commence as of the Effective Date
and, unless sooner terminated as provided hereunder, shall expire as
follows:
(a) As to each Vaccine Product in each country in the
Territory, this Agreement shall expire upon the expiration of the Royalty
Term with respect to such Vaccine Product in such country.
(b) This Agreement shall expire in its entirety upon the
termination of the Royalty Term with respect to all Vaccine Products in all
countries in the Territory.
12.2 Breach.
(a) Failure by either Party to comply with any of its material
obligations contained in this Agreement shall entitle the other Party to
give to the Party in default notice specifying the nature of the default
and requiring it to cure such default. If such default is not cured within
60 days (30 days in the event of a default with respect to an obligation to
pay money) after the receipt of such notice (or, if such default cannot be
cured within such 60-day period, if the Party in default does not commence
and diligently continue actions to cure such default, the Parties agreeing
that all defaults with respect to obligations to pay money shall be curable
within the 30-day period provided above), subject to the provisions of
Sections 4.8 and 5.3, the notifying Party shall be entitled, without
prejudice to any of its other rights conferred on it by this Agreement, and
in addition to any other remedies available to it by law or in equity, to
terminate this Agreement in its entirety, by giving written notice to take
effect immediately upon delivery of such notice. The right of either Party
to terminate this Agreement, as provided in this Section 12.2, shall not be
affected in any way by its waiver or failure to take action with respect to
any previous default.
(b) An election of remedy by a Party for a material breach of
this Agreement under this Section 12.2 on one occasion shall not constitute
a waiver as to any other remedy that may be available to such Party under
this Section 12.2 as to any material breach on another occasion.
(c) After Phase II is completed, , SB may terminate this
Agreement by giving sixty (60) days' written notice to MEDIMMUNE but only
if (i) further development and commercialization of Vaccine Product is not
economically feasible or (ii) the technical and clinical information
indicates that there are material concerns about the safety or efficacy of
the Vaccine Product.
(d) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(e) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
12.3 Effect of Expiration or Termination.
(a) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(b) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(PAGE 24)
(c) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(d) (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
12.4 Either party may terminate this Agreement, if, at any time, the
other party shall file in any court or agency pursuant to any statute or
regulation of a country in the Territory a petition of bankruptcy or
insolvency or for reorganization or for an arrangement or for the
appointment of a receiver of trustee of the party or of its assets or if
the other party proposes a written agreement of composition or extension of
its debts or if the other party shall be served with an involuntary
petition against it, filed in any insolvency proceeding, and such petition
shall not be dismissed within 60 days after filing thereof, or if the other
party shall make an assignment for the benefit of its creditors.
Notwithstanding the bankruptcy of MEDIMMUNE or the impairment of
performance of MEDIMMUNE of its obligations under this section, SB shall be
entitled to retain the licenses granted herein, provided it continues to
comply with its obligations to MEDIMMUNE hereunder.
12.5 Right to Sell Stock on Hand. Upon the termination of any
rights granted hereunder, in whole or in part as to any Vaccine Product in
any country in the Territory, for any reason other than a failure to cure a
material breach of this Agreement by SB, SB shall have the right to dispose
of all Vaccine Product then on hand to which such termination applies, and
the royalties shall be paid to MEDIMMUNE with respect to such Vaccine
Product as though such rights had not terminated.
12.6 Accrued Rights, Surviving Obligations.
(a) Termination, relinquishment or expiration of this
Agreement for any reason shall be without prejudice to any rights which
shall have accrued to the benefit of either Party prior to such
termination, relinquishment or expiration. Such termination,
relinquishment or expiration shall not relieve either Party from
obligations which are expressly indicated to survive termination or
expiration of this Agreement.
(b) Termination, relinquishment or expiration of this
Agreement shall not terminate SB's obligation to pay all royalties and
milestone payments that shall have accrued prior to such termination. All
of the Parties' rights and obligations under Sections 2.2(b), 8.4 10, 11,
12.3 12.4, 12.5, 12.6, 14.11 and 14.17 shall survive termination,
relinquishment or expiration hereof.
12.7 Termination for Failure of Condition. Either Party may
terminate this Agreement by providing written notice to the other in the
event that Effective Date has not occurred by June 30, 1998.
13. FORCE MAJEURE.
13.1 Events of Force Majeure. Except for payments due under this
Agreement, neither Party shall be held liable or responsible to the other
Party nor be deemed to be in default under or in breach of any provision of
this Agreement for failure or delay in fulfilling or performing any
obligation of this Agreement when such failure or delay is due to force
majeure, and without the fault or negligence of the Party so failing or
(PAGE 25)
delaying. For purposes of this Agreement, force majeure is defined as
causes beyond the control of the Party, including, without limitation, acts
of God; acts, regulations, or laws of any government; war; civil commotion;
destruction of production facilities or materials by fire, flood,
earthquake, explosion or storm; labor disturbances; epidemic; and failure
of pubic utilities or common carriers. In such event SB or MEDIMMUNE, as
the case may be, shall immediately notify the other Party of such inability
and of the period for which such inability is expected to continue. The
Party giving such notice shall thereupon be excused from such of its
obligations under this Agreement as it is thereby disabled from performing
for so long as it is so disabled and the 30 days thereafter. To the extent
possible, each Party shall use reasonable efforts to minimize the duration
of any force majeure.
14. MISCELLANEOUS.
14.1 Relationship of Parties. Nothing in this Agreement is intended
or shall be deemed to constitute a partnership, agency, employer-employee
or joint venture relationship between the Parties. No Party shall incur
any debts or make any commitments for the other, except to the extent, if
at all, specifically provided herein.
14.2 Assignment. (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
14.3 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of
this Agreement.
14.4 Notice. Any notice or request required or permitted to be
given under or in connection with this Agreement shall be deemed to have
been sufficiently given if in writing and personally delivered or sent by
certified mail (return receipt requested), facsimile transmission (receipt
verified), or overnight express courier service (signature required),
prepaid, to the Party for which such notice is intended, at the address set
forth for such Party below:
(a) In the case of SB, to:
SmithKline Xxxxxxx, PLC
c/o SmithKline Xxxxxxx Biologicals Manufacturing X.X.
Xxx de l'Institut 89
X-0000 Xxxxxxxxx, Xxxxxxx
Attention: Senior Vice President
(b) In the case of MEDIMMUNE, to:
MEDIMMUNE, Inc.
00 Xxxx Xxxxxxx Xxxx Xxxx
Xxxxxxxxxxxx, Xxxxxxxx 00000
Attention: President
Facsimile No.: (000) 000-0000
or to such other address for such Party as it shall have specified by like
notice to the other Party, provided that notices of a change of address
shall be effective only upon receipt thereof. If delivered personally or
by
(PAGE 26)
facsimile transmission, the date of delivery shall be deemed to be the date
on which such notice or request was given. If sent by overnight express
courier service, the date of delivery shall be deemed to be the next
business day after such notice or request was deposited with such service.
If sent by certified mail, the date of delivery shall be deemed to be the
third business day after such notice or request was deposited with the U.S.
Postal Service.
14.5 Use of Name. Except as otherwise provided herein, neither
Party shall have any right, express or implied, to use in any manner the
name or other designation of the other Party or any other trade name or
trademark of the other Party for any purpose in connection with the
performance of this Agreement.
14.6 Public Announcements. Except as required by law (including,
without limitation, disclosure requirements of the U.S. Securities and
Exchange Commission, Nasdaq or any other stock exchange on which securities
issued by MEDIMMUNE are traded), neither Party shall make any public
announcement concerning this Agreement or the subject matter hereof without
the prior written consent of the other, which shall not be unreasonably
withheld. It shall not be unreasonable for a Party to withhold consent
with respect to any public announcement containing any of such Party's
Confidential Information. In the event of a required public announcement,
to the extent practicable under the circumstances, the Party making such
announcement shall provide the other Party with a copy of the proposed text
prior to such announcement sufficiently in advance of the scheduled release
of such announcement to afford such other Party a reasonable opportunity to
review and comment upon the proposed text.
14.7 Waiver. A waiver by either Party of any of the terms and
conditions of this Agreement in any instance shall not be deemed or
construed to be a waiver of such term or condition for the future, or of
any subsequent breach hereof. All rights, remedies, undertakings,
obligations and agreements contained in this Agreement shall be cumulative
and none of them shall be in limitation of any other remedy, right,
undertaking, obligation or agreement of either Party.
14.8 Compliance with Law. Nothing in this Agreement shall be deemed
to permit a Party to export, reexport or otherwise transfer any Vaccine
Product sold under this Agreement without compliance with applicable laws.
14.9 Severability. When possible, each provision of this Agreement
will be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement is held to be
prohibited by or invalid under applicable law, such provision will be
ineffective only to the extent of such prohibition or invalidity, without
invalidating the remainder of this Agreement and the parties shall
negotiate, in good faith, a new provision which will, as closely as
possible, carry out the intentions of the parties provided for in the
invalidated provision.
14.10 Amendment. No amendment, modification or supplement of any
provisions of this Agreement shall be valid or effective unless made in
writing and signed by a duly authorized officer of each Party.
(PAGE 27)
14.11 Governing Law. This Agreement shall be governed by and
interpreted in accordance with the laws of the State of Maryland without
regard to its choice of law principles. In the event that either Party
desires to initiate litigation with respect to this Agreement, such
litigation shall be conducted in an appropriate court in the State of
Maryland and each Party hereby submits to the jurisdiction of such court(s)
and agrees that venue is proper in such court(s).
14.12 Entire Agreement. This Agreement, together with the Exhibits
hereto and every Annual Research Plan approved by the Steering Committee,
sets forth the entire agreement and understanding between the Parties as to
the subject matter hereof and merges all prior discussions and negotiations
between them, and neither of the Parties shall be bound by any conditions,
definitions, warranties, understandings or representations with respect to
such subject matter other than as expressly provided herein or as duly set
forth on or subsequent to the date hereof in writing and signed by a proper
and duly authorized officer or representative of the Party to be bound
thereby.
14.13 Parties in Interest. All the terms and provisions of this
Agreement shall be binding upon, inure to the benefit of and be enforceable
by the Parties hereto and their respective permitted successors and
assigns.
14.14 Descriptive Headings. The descriptive headings of this
Agreement are for convenience only, and shall be of no force or effect in
construing or interpreting any of the provisions of this Agreement.
14.15 Counterparts. This Agreement may be executed simultaneously in
any number of counterparts, any one of which need not contain the signature
of more than one Party but all such counterparts taken together shall
constitute one and the same agreement.
14.16 (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
14.17 (CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(PAGE 28)
IN WITNESS WHEREOF, each of the Parties has caused this Agreement to
be executed by its duly authorized officer as of the day and year first
above written.
SMITHKLINE XXXXXXX , PLC
By: /s/J. Stephenne
Name: J. Stephenne
Title: Senior Vice President and
General Manager
MEDIMMUNE, INC.
By: /s/Xxxxx X. Xxxxxxxxx
Name: Xxxxx X. Xxxxxxxxx
Title: CEO
SCHEDULE A
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
SCHEDULE B
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
SCHEDULE C
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
SCHEDULE D
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
SCHEDULE A
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
SCHEDULE B
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
SCHEDULE C
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
SCHEDULE D
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED)
(PAGE 29)
